バイオシミュレーション市場規模、シェア、動向、2031年までの世界予測

バイオシミュレーション市場は、2026年の42億7,000万米ドルから2031年には92億4,000万米ドルに達し、同期間の年平均成長率（CAGR）は16.7%に達するとMarketsandMarketsでは予測しています。この市場の成長を牽引しているのは、創薬・開発プロセスの複雑化、研究開発（R&D）の生産性向上に対する圧力の高まり、そして予測モデリング手法を用いて後期臨床試験での失敗を減らす必要性の増大です。製薬企業やバイオテクノロジー企業は、多額の費用を要する実験室試験や臨床試験に化合物を進める前に、バイオシミュレーション技術を活用して、候補薬の評価、投与戦略の最適化、安全性や有効性の予測、さらには規制当局の意思決定支援を行っています。

さらに、規制当局による「モデル情報に基づく医薬品開発（MIDD）」アプローチの認知度も高まっています。2025年1月、医薬品規制調和国際会議（ICH）は、MIDDに関するM15ガイドラインをステップ4として採択しました。これにより、規制当局への申請や医薬品開発プログラムにおいて、モデリングおよびシミュレーションを適用するための調和された枠組みが提供されることになります。加えて、製薬R&D支出の継続的な増加や、人工知能（AI）、機械学習、デジタル創薬技術の導入拡大が、高度なバイオシミュレーション・プラットフォームへの需要を加速させています。しかし、ソフトウェアの導入やモデル開発に伴う高コスト、データ品質やモデルの妥当性確認（バリデーション）に関する課題、熟練したファーマコメトリシャンや計算科学者の不足、そして多様な研究環境間での統合の複雑さといった要因が、市場の成長を抑制する可能性があります。

調査対象範囲：

本調査レポートでは、バイオシミュレーション市場を以下の区分で分類しています：提供形態（ソフトウェア、サービス）、開発段階（創薬、前臨床開発、初期臨床開発、後期臨床開発、規制対応、商業化・市場アクセス）、モダリティ（抗体設計、ペプチド探索、酵素工学、二機能性分解剤、TCRモデリング、その他）、用途（分子設計・最適化、PK/PDモデリング、PBPKモデリング、定量的システム薬理学（QSP）、ADME/毒性予測、臨床試験シミュレーション、疾患モデリング、その他）、治療領域（腫瘍学、心血管疾患、神経疾患、感染症、代謝・内分泌疾患、その他）、導入形態（オンプレミス型、クラウド型、ハイブリッド型）、エンドユーザー（製薬・バイオテクノロジー企業、受託研究機関（CRO）、学術・研究機関、規制当局、その他）、および地域（北米、欧州、アジア太平洋、中南米、中東・アフリカ）。本レポートでは、バイオシミュレーション市場の成長に影響を与える主要因（促進要因、抑制要因、課題、機会など）に関する詳細情報を取り上げています。主要な業界プレーヤーについて詳細な分析を行い、事業概要、ソリューション・サービス、主要戦略、契約・提携・合意、新製品・サービスの投入、M&A、および市場に関連する最近の動向についての知見を提供します。また、バイオシミュレーション市場のエコシステムにおける新興スタートアップ企業の競争分析も含まれています。

本レポートを購入する理由

本レポートは、既存企業および新規参入企業・小規模企業が市場の動向を把握し、市場シェア拡大につなげる一助となります。本レポートを購入した企業は、以下に挙げる戦略のいずれか、またはそれらを組み合わせた戦略を採用することで、市場における自社の地位を強化することが可能になります。

本レポートでは、以下の点に関する知見を提供します。

バイオシミュレーション市場の成長に影響を与える要因の分析：主要な促進要因（製薬・バイオテクノロジー業界におけるR&D投資の増加、規制当局によるバイオシミュレーション・ソフトウェアの採用拡大、技術的に高度な定量的システム薬理学（QSP）の統合、創薬・開発コスト削減の必要性）、阻害要因（標準化の欠如、データの可用性と品質）、機会（新規治療モダリティへの展開、小児用医薬品開発におけるバイオシミュレーション・ソリューションの活用）、および課題（生体システムやプロセスの複雑さへの対応の難しさ、バイオシミュレーションおよびモデリングの専門家不足）。

• 製品開発・イノベーション：バイオシミュレーション市場における次世代技術、研究開発活動、新製品投入に関する詳細な知見。
• 市場展開：有望な新興市場、提供製品・サービス、開発段階、モダリティ、用途、治療領域、導入形態、エンドユーザー、地域に関する包括的な情報。
• 市場の多角化：バイオシミュレーション市場における製品ポートフォリオ、成長地域、最近の動向、投資状況に関する網羅的な情報。
• 競合分析：Certara（米国）、Dassault Systèmes（フランス）、Schrödinger, Inc.（米国）、Simulations Plus（米国）、Advanced Chemistry Development, Inc. (Revvity)（カナダ）といった主要企業の市場シェア、成長戦略、製品・サービス、能力に関する詳細な評価。

Report Description

The biosimulation market is projected to reach USD 9.24 billion by 2031 from USD 4.27 billion in 2026, at a CAGR of 16.7% from 2026 to 2031. The growth of the biosimulation market is being driven by the increasing complexity of drug discovery and development, rising pressure to improve R&D productivity, and the growing need to reduce late-stage clinical failures through predictive modeling approaches. Pharmaceutical and biotechnology companies are increasingly utilizing biosimulation technologies to evaluate drug candidates, optimize dosing strategies, predict safety and efficacy outcomes, and support regulatory decision-making before advancing compounds into costly laboratory and clinical studies. Furthermore, regulatory agencies are increasingly recognizing model-informed drug development (MIDD) approaches. In January ‘25, the International Council for Harmonisation (ICH) reached Step 4 adoption of the M15 Guideline on Model-Informed Drug Development, providing a harmonized framework for the application of modeling and simulation in regulatory submissions and drug development programs. In addition, continued growth in pharmaceutical R&D spending and the increasing adoption of artificial intelligence, machine learning, and digital drug development technologies are accelerating demand for advanced biosimulation platforms. However, market growth may be constrained by the high costs associated with software implementation and model development, challenges related to data quality and model validation, limited availability of skilled pharmacometricians and computational scientists, and integration complexities across diverse research environments.

“In 2025, the pharmaceutical & biotechnology companies segment accounted for the largest market share, by end user.”

By end user, pharmaceutical and biotechnology companies represented the largest share of the biosimulation market in 2025. Their leadership stems from the growing need to improve drug development efficiency, increase the probability of clinical success, and manage increasingly complex therapeutic pipelines. These organizations extensively utilize biosimulation tools to support compound screening, translational research, exposure-response analysis, clinical trial optimization, and regulatory interactions. The rising focus on innovative modalities such as biologics, gene therapies, mRNA-based therapeutics, and precision medicine has further increased reliance on advanced modeling and simulation technologies. Moreover, the need to reduce attrition rates, accelerate time-to-market, and maximize returns on R&D investments has encouraged pharmaceutical and biotechnology companies to incorporate biosimulation across multiple stages of the drug development process, strengthening their position as the largest end-user segment in the market.

“The cloud-based models segment by deployment mode is expected to register the fastest growth during the forecast period.”

By deployment mode, cloud-based solutions are expected to be the fastest-growing segment in the biosimulation market during the forecast period. This growth is driven by the increasing need for scalable computing resources, collaborative research environments, and cost-effective access to advanced modeling and simulation capabilities. Cloud-based platforms enable pharmaceutical and biotechnology companies to perform computationally intensive tasks such as PBPK modeling, QSP, molecular dynamics, AI-driven drug discovery, and virtual patient simulations without significant investments in on-premises infrastructure. These solutions also facilitate seamless data sharing, global collaboration, and faster model deployment across geographically distributed research teams. Furthermore, the growing integration of artificial intelligence, machine learning, and high-performance computing with cloud environments is accelerating the adoption of cloud-based biosimulation platforms, particularly among small and mid-sized organizations seeking greater flexibility and reduced operational costs.

“Asia Pacific is expected to witness the highest growth rate during the forecast period.”

The Asia Pacific region is projected to experience the highest growth rate in the biosimulation market over the forecast period. Key factors driving this growth include expanding pharmaceutical and biotechnology R&D activities, increasing adoption of AI-driven drug discovery technologies, rising demand for cost-effective drug development strategies, and growing investments in computational biology and precision medicine. Countries such as China, India, Japan, South Korea, and Singapore are strengthening their life sciences ecosystems through government-backed innovation programs, expanding biopharmaceutical manufacturing capabilities, and the growing use of advanced modeling and simulation tools across research workflows. Furthermore, the increasing presence of global pharmaceutical companies, contract research organizations, and academic research institutes is accelerating the adoption of biosimulation platforms in the region. Recent developments also highlight the region’s momentum; in May 2025, Insilico Medicine announced the global expansion of its research and development operations to further advance AI-powered drug discovery and development, reinforcing Asia Pacific’s position as a key hub for innovation in computational life sciences and biosimulation.

The breakdown of primary participants is as mentioned below:

• By Company Type – Tier 1: 34%, Tier 2: 46%, and Tier 3: 20%
• By Designation – C-level: 35%, Director-level: 25%, and Others: 40%
• By Region – North America: 30%, Europe: 45%, Asia Pacific: 20%, Middle East & Africa: 3%, Latin America: 2%

Key Market Players

The key players in the biosimulation market include Certara (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Simulations Plus (US), and Advanced Chemistry Development, Inc. (Revvity) (Canada).

Research Coverage:

This research report categorizes the biosimulation market based on offering (software, services), phase of development (drug discovery, preclinical development, early clinical development, late clinical development, regulatory, commercial & market access), modality (antibody design, peptide discovery, enzyme engineering, bifunctional degraders, TCR modeling, others), application (molecular design & optimization, PK/PD modeling, PBPK modeling, quantitative systems pharmacology (QSP), ADME/toxicity prediction, clinical trial simulation, disease modeling, other applications), therapeutic area (oncology, cardiovascular diseases, neurological disorders, infectious diseases, metabolic & endocrine disorders, other therapeutic areas), deployment mode (on-premises models, cloud-based models, hybrid models), end user (pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, regulatory bodies, other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimulation market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions; and recent developments associated with the biosimulation market. Competitive analysis of upcoming startups in the biosimulation market ecosystem is covered in this report.

Reasons to Buy the Report

This report will help established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them gain a greater share of the market. Firms purchasing the report could use one or a combination of the following strategies to strengthen their positions in the market.

This report provides insights on:

Analysis of key drivers (Increasing R&D investments in pharmaceutical and biotechnology industries, Growing adoption of biosimulation software by regulatory bodies, Integration of technologically advanced quantitative systems pharmacology (QSP), Need to curtail drug discovery and development costs), restraints (Lack of standardization, Data availability and quality), opportunities (Expansion into novel therapeutic modalities, Use of biosimulation solutions for pediatric drug development), and challenges (Difficulties in matching complexity of biological systems and processes, Shortage of biosimulation and modeling experts) influencing the growth of the biosimulation market.

• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the biosimulation market.
• Market Development: Comprehensive information on the lucrative emerging markets, offerings, phases of development, modalities, applications, therapeutic areas, deployment modes, end users, and regions.
• Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the biosimulation market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players, such as Certara (US), Dassault Systèmes (France), Schrödinger, Inc. (US), Simulations Plus (US), Advanced Chemistry Development, Inc. (Revvity) (Canada), in the biosimulation market.

Table of Contents

1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 MARKET SCOPE 35
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 37
1.4 CURRENCY CONSIDERED 38
1.5 LIMITATIONS 38
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 40
2 EXECUTIVE SUMMARY 41
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 41
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 43
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 44
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 45
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 46
3 PREMIUM INSIGHTS 48
3.1 BIOSIMULATION MARKET OVERVIEW 48
3.2 BIOSIMULATION MARKET, BY OFFERING & REGION 49
3.3 BIOSIMULATION MARKET: GEOGRAPHIC SNAPSHOT 50
4 MARKET OVERVIEW 51
4.1 INTRODUCTION 51
4.2 MARKET DYNAMICS 52
4.2.1 DRIVERS 52
4.2.1.1 Increasing R&D investments in pharmaceutical and biotechnology industries 52
4.2.1.2 Growing adoption of biosimulation software by regulatory bodies 53
4.2.1.3 Integration of technologically advanced quantitative systems pharmacology 54
4.2.1.4 Need to curtail drug discovery and development costs 54
4.2.2 RESTRAINTS 55
4.2.2.1 Lack of standardization 55
4.2.2.2 Data availability and quality 55
4.2.3 OPPORTUNITIES 56
4.2.3.1 Expansion into novel therapeutic modalities 56
4.2.3.2 Use of biosimulation solutions for pediatric drug development 56
4.2.4 CHALLENGES 56
4.2.4.1 Difficulties in matching complexity of biological systems and processes 56
4.2.4.2 Shortage of biosimulation and modeling experts 57
4.3 UNMET NEEDS AND WHITE SPACES 57
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 58
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 58
5 INDUSTRY TRENDS 60
5.1 PORTER’S FIVE FORCES ANALYSIS 60
5.1.1 BARGAINING POWER OF SUPPLIERS 61
5.1.2 BARGAINING POWER OF BUYERS 61
5.1.3 THREAT OF SUBSTITUTES 61
5.1.4 THREAT OF NEW ENTRANTS 61
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 62
5.2 MACROECONOMIC INDICATORS 62
5.2.1 INTRODUCTION 62
5.2.2 GDP TRENDS AND FORECAST 62
5.2.3 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY 62
5.3 VALUE CHAIN ANALYSIS 63
5.3.1 RESEARCH & PRODUCT DEVELOPMENT 64
5.3.2 DATA INPUTS & COMPUTATIONAL INFRASTRUCTURE 64
5.3.3 PLATFORM DEVELOPMENT AND INTEGRATION 64
5.3.4 DISTRIBUTION 65
5.3.5 MARKETING AND SALES 65
5.3.6 POST-SALES SERVICES 65
5.4 ECOSYSTEM ANALYSIS 65
5.5 PRICING ANALYSIS 67
5.5.1 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY OFFERING (2025) 67
5.5.2 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY REGION (2025) 68
5.6 KEY CONFERENCES AND EVENTS, 2026–2027 68
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 69
5.8 INVESTMENT AND FUNDING SCENARIO 70
5.9 CASE STUDY ANALYSIS 71
5.10 IMPACT OF 2025 US TARIFF – BIOSIMULATION MARKET 73
5.10.1 INTRODUCTION 73
5.10.2 KEY TARIFF RATES 74
5.10.3 PRICE IMPACT ANALYSIS 75
5.10.4 IMPACT ON COUNTRY/REGION 75
5.10.4.1 US 75
5.10.4.2 Europe 75
5.10.4.3 Asia Pacific 75
5.10.5 IMPACT ON END-USE INDUSTRIES 76
5.10.5.1 Pharmaceutical and Biotechnology Companies 76
5.10.5.2 Contract Research Organizations 76
5.10.5.3 Academic & Research Institutes 76
5.10.5.4 Regulatory Bodies 76
5.10.5.5 Other End Users 76
6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL,
AND AI ADOPTION 77
6.1 KEY EMERGING TECHNOLOGIES 77
6.1.1 MATHEMATICAL MODELING 77
6.1.2 POPULATION PK MODELING 77
6.1.3 MOLECULAR MODELING & SIMULATION 78
6.2 COMPLEMENTARY TECHNOLOGIES 78
6.2.1 DATA ANALYTICS 78
6.2.2 ARTIFICIAL INTELLIGENCE 78
6.3 ADJACENT TECHNOLOGIES 79
6.3.1 COMPUTATIONAL CHEMISTRY 79
6.3.2 AI-DRIVEN DRUG DISCOVERY 79
6.4 TECHNOLOGY/PRODUCT ROADMAP 79
6.5 PATENT ANALYSIS 80
6.5.1 PATENT PUBLICATION TRENDS FOR BIOSIMULATION MARKET 80
6.5.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 81
6.6 FUTURE APPLICATIONS 83
6.6.1 AI-ENABLED INTELLIGENT MODELING AND PREDICTION 84
6.6.2 VIRTUAL CLINICAL TRIALS AND DIGITAL PATIENT COHORTS 84
6.6.3 MULTI-SCALE BIOLOGICAL SYSTEMS SIMULATION 84
6.7 IMPACT OF AI/GEN AI ON BIOSIMULATION MARKET 84
6.7.1 INTRODUCTION 84
6.7.2 MARKET POTENTIAL OF AI/GEN AI IN BIOSIMULATION MARKET 85
6.7.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION 86
6.7.3.1 Artificial intelligence in drug discovery and development 86
6.7.4 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 87
6.7.4.1 AI-Driven Drug Discovery Market 87
6.7.4.2 Digital Twin Healthcare Market 87
6.7.4.3 Real-World Evidence (RWE) Market 87
6.7.5 USER READINESS AND IMPACT ASSESSMENT 88
6.7.5.1 User readiness 88
6.7.5.1.1 User A: Pharmaceutical & biotechnology companies 88
6.7.5.1.2 User B: Contract research organizations (CROs) 88
6.7.5.2 Impact assessment 89
6.7.5.2.1 User A: Pharmaceutical & biotechnology companies 89
6.7.5.2.1.1 Implementation 89
6.7.5.2.1.2 Impact 89
6.7.5.2.2 User B: Contract research organizations 89
6.7.5.2.2.1 Implementation 89
6.7.5.2.2.2 Impact 89
7 REGULATORY LANDSCAPE 90
7.1 REGIONAL REGULATIONS AND COMPLIANCE 90
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS 91
7.1.2 REGULATORY FRAMEWORK 94
7.1.2.1 North America 94
7.1.2.2 Europe 94
7.1.2.3 Asia Pacific 95
7.1.2.4 Latin America 95
7.1.2.5 Middle East & Africa 96
7.1.3 INDUSTRY STANDARDS 96
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 98
8.1 INTRODUCTION 98
8.2 DECISION-MAKING PROCESS 98
8.3 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 98
8.3.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
8.3.2 BUYING CRITERIA 99
8.4 ADOPTION BARRIERS & INTERNAL CHALLENGES 100
8.5 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 101
8.5.1 UNMET NEEDS 101
8.5.2 END-USER EXPECTATIONS 102
8.6 MARKET PROFITABILITY 103
9 BIOSIMULATION MARKET, BY OFFERING 104
9.1 INTRODUCTION 105
9.2 SOFTWARE 105
9.2.1 AI-ENABLED PLATFORMS AND MODEL-INFORMED DRUG DEVELOPMENT DRIVE MARKET EXPANSION 105
9.3 SERVICES 106
9.3.1 CONSULTING & ADVISORY 108
9.3.1.1 Strategic R&D decision-making and biosimulation integration drive growth in consulting services 108
9.3.2 IMPLEMENTATION, TRAINING, AND SUPPORT 109
9.3.2.1 Growing enterprise-wide adoption of biosimulation platforms fuels demand 109
9.3.3 DATA ANALYSIS & INTERPRETATION 110
9.3.3.1 Expanding scientific data volumes and demand for actionable insights drive growth 110
10 BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT 112
10.1 INTRODUCTION 113
10.2 DRUG DISCOVERY 113
10.2.1 AI-DRIVEN MOLECULAR DESIGN AND VIRTUAL SCREENING STRENGTHEN BIOSIMULATION USE IN EARLY RESEARCH 113
10.3 PRECLINICAL DEVELOPMENT 115
10.3.1 GROWING EMPHASIS ON REDUCING ANIMAL TESTING AND IMPROVING TRANSLATIONAL PREDICTABILITY DRIVES BIOSIMULATION ADOPTION 115
10.4 EARLY CLINICAL DEVELOPMENT 116
10.4.1 RISING DEMAND FOR FIRST-IN-HUMAN DOSE OPTIMIZATION AND TRIAL DESIGN EFFICIENCY DRIVES BIOSIMULATION ADOPTION 116
10.5 LATE CLINICAL DEVELOPMENT 117
10.5.1 GROWING NEED FOR TRIAL OPTIMIZATION AND EVIDENCE GENERATION IN LARGE-SCALE STUDIES DRIVES BIOSIMULATION ADOPTION 117
10.6 REGULATORY 118
10.6.1 INCREASING USE OF QUANTITATIVE EVIDENCE IN REGULATORY SUBMISSIONS DRIVES BIOSIMULATION ADOPTION 118
10.7 COMMERCIAL & MARKET ACCESS 119
10.7.1 EXPANDING USE OF HEALTH ECONOMIC MODELING AND REAL-WORLD EVIDENCE ENHANCES MARKET ACCESS STRATEGIES 119
11 BIOSIMULATION MARKET, BY MODALITY 120
11.1 INTRODUCTION 121
11.2 ANTIBODY DESIGN 121
11.2.1 AI-BASED PROTEIN ENGINEERING AND RISING BIOLOGICS PIPELINES ACCELERATE BIOSIMULATION USE IN ANTIBODY DESIGN 121
11.3 PEPTIDE DISCOVERY 122
11.3.1 ADVANCEMENTS IN THERAPEUTIC PEPTIDE ENGINEERING AND AI-DRIVEN SEQUENCE OPTIMIZATION FUEL BIOSIMULATION ADOPTION 122
11.4 ENZYME ENGINEERING 123
11.4.1 INCREASING ADOPTION OF COMPUTATIONAL PROTEIN DESIGN ACCELERATES BIOSIMULATION USE IN ENZYME DEVELOPMENT 123
11.5 BIFUNCTIONAL DEGRADERS 124
11.5.1 RISING INTEREST IN TARGETED PROTEIN DEGRADATION DRIVES BIOSIMULATION ADOPTION 124
11.6 TCR MODELING 125
11.6.1 EXPANDING CELL THERAPY RESEARCH AND PRECISION IMMUNOTHERAPY DEVELOPMENT DRIVE ADOPTION 125
11.7 OTHER MODALITIES 126
11.7.1 ADVANCES IN COMPUTATIONAL DRUG DESIGN AND NEXT-GENERATION NUCLEIC ACID THERAPIES EXPAND APPLICATIONS 126
12 BIOSIMULATION MARKET, BY APPLICATION 128
12.1 INTRODUCTION 129
12.2 MOLECULAR DESIGN & OPTIMIZATION 129
12.2.1 AI-ENABLED MOLECULAR GENERATION AND CLOUD-BASED DESIGN PLATFORMS ACCELERATE LEAD OPTIMIZATION 129
12.3 PK/PD MODELING 130
12.3.1 INCREASING FOCUS ON EXPOSURE-RESPONSE UNDERSTANDING AND PRECISION DOSING EXPANDS PK/PD MODELING ADOPTION 130
12.4 PBPK MODELING 132
12.4.1 GROWING NEED FOR PREDICTIVE HUMAN PHARMACOKINETIC ASSESSMENTS DRIVES ADOPTION OF PBPK MODELING 132
12.5 QUANTITATIVE SYSTEMS PHARMACOLOGY 133
12.5.1 INCREASING FOCUS ON MECHANISTIC DISEASE UNDERSTANDING AND PRECISION THERAPEUTICS DRIVES ADOPTION 133
12.6 ADME/TOXICITY PREDICTION 134
12.6.1 GROWING EMPHASIS ON EARLY SAFETY ASSESSMENT AND CANDIDATE QUALITY IMPROVEMENT DRIVES ADME/TOXICITY MODELING ADOPTION 134
12.7 CLINICAL TRIAL SIMULATION 135
12.7.1 INCREASING CLINICAL TRIAL VOLUMES AND STUDY COMPLEXITY DRIVE ADOPTION OF SIMULATION-BASED DEVELOPMENT STRATEGIES 135
12.8 DISEASE MODELING 136
12.8.1 GROWING FOCUS ON PRECISION MEDICINE AND MECHANISTIC UNDERSTANDING OF COMPLEX DISEASES DRIVES ADOPTION 136
12.9 OTHER APPLICATIONS 137
12.9.1 ADVANCEMENTS IN SYSTEMS-LEVEL BIOLOGICAL ANALYSIS AND FORMULATION OPTIMIZATION EXPAND BIOSIMULATION APPLICATIONS 137
13 BIOSIMULATION MARKET, BY THERAPEUTIC AREA 139
13.1 INTRODUCTION 140
13.2 ONCOLOGY 140
13.2.1 EXPANDING PRECISION ONCOLOGY RESEARCH AND RISING CANCER TRIAL ACTIVITY ACCELERATE BIOSIMULATION ADOPTION 140
13.3 CARDIOVASCULAR DISEASES 141
13.3.1 RISING BURDEN OF CARDIOVASCULAR DISORDERS AND EXPANSION OF LARGE-SCALE OUTCOME TRIALS DRIVE BIOSIMULATION ADOPTION 141
13.4 NEUROLOGICAL DISORDERS 142
13.4.1 HIGH CNS TRIAL FAILURE AND ACCESS BARRIERS STRENGTHEN NEED FOR BIOSIMULATION IN NEUROLOGY DEVELOPMENT 142
13.5 INFECTIOUS DISEASES 143
13.5.1 PERSISTENT GLOBAL DISEASE BURDEN AND OUTBREAK PREPAREDNESS NEEDS DRIVE BIOSIMULATION ADOPTION 143
13.6 METABOLIC & ENDOCRINE DISORDERS 144
13.6.1 RISING DIABETES AND OBESITY BURDEN EXPANDS NEED FOR SIMULATION-DRIVEN METABOLIC DRUG DEVELOPMENT 144
13.7 OTHER THERAPEUTIC AREAS 145
13.7.1 EXPANSION OF RARE DISEASE, IMMUNOLOGY, RESPIRATORY, GASTROINTESTINAL, AND RENAL DRUG DEVELOPMENT BROADENS BIOSIMULATION APPLICATIONS 145
14 BIOSIMULATION MARKET, BY DEPLOYMENT MODE 147
14.1 INTRODUCTION 148
14.2 ON-PREMISES 148
14.2.1 ESTABLISHED INFRASTRUCTURE AND DATA GOVERNANCE REQUIREMENTS SUSTAIN ADOPTION 148
14.3 CLOUD-BASED MODELS 149
14.3.1 SCALABLE COMPUTING INFRASTRUCTURE AND AI-DRIVEN RESEARCH WORKFLOWS ACCELERATE CLOUD ADOPTION 149
14.4 HYBRID MODELS 150
14.4.1 BALANCING SECURITY AND SCALABILITY ENCOURAGES ADOPTION OF HYBRID DEPLOYMENT STRATEGIES 150
15 BIOSIMULATION MARKET, BY END USER 152
15.1 INTRODUCTION 153
15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 153
15.2.1 HIGH R&D SPENDING AND EXPANDING DRUG PIPELINES DRIVE BIOSIMULATION ADOPTION AMONG PHARMA & BIOTECH COMPANIES 153
15.3 CONTRACT RESEARCH ORGANIZATIONS 154
15.3.1 GROWING OUTSOURCING OF DRUG DEVELOPMENT ACTIVITIES EXPANDS BIOSIMULATION ADOPTION AMONG CROS 154
15.4 CONSULTING SERVICE COMPANIES 155
15.4.1 EXPANDING COMPUTATIONAL RESEARCH AND PUBLIC FUNDING INITIATIVES SUPPORT BIOSIMULATION ADOPTION IN ACADEMIA 155
15.5 REGULATORY BODIES 156
15.5.1 GROWING ACCEPTANCE OF MODEL-INFORMED EVIDENCE STRENGTHENS BIOSIMULATION ADOPTION AMONG REGULATORY AGENCIES 156
15.6 OTHER END USERS 157
15.6.1 EXPANDING USE OF COMPUTATIONAL MODELING BEYOND TRADITIONAL DRUG DEVELOPMENT BROADENS BIOSIMULATION ADOPTION 157
16 BIOSIMULATION MARKET, BY REGION 159
16.1 INTRODUCTION 160
16.2 NORTH AMERICA 160
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 161
16.2.2 US 165
16.2.2.1 Regulatory science and AI-driven innovation accelerate biosimulation adoption 165
16.2.3 CANADA 169
16.2.3.1 Expanding computational drug research strengthens biosimulation adoption 169
16.3 EUROPE 174
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175
16.3.2 GERMANY 179
16.3.2.1 Strong pharmaceutical research base drives advanced modeling adoption 179
16.3.3 FRANCE 183
16.3.3.1 Biopharma innovation and research commercialization support market expansion 183
16.3.4 UK 187
16.3.4.1 Regulatory innovation and AI drug discovery accelerate adoption 187
16.3.5 ITALY 191
16.3.5.1 Research modernization efforts create opportunities for computational development 191
16.3.6 SPAIN 195
16.3.6.1 Expanding clinical trial leadership creates need for development efficiency 195
16.3.7 REST OF EUROPE 199
16.4 ASIA PACIFIC 204
16.4.1 CLINICAL TRIAL INITIATIONS IN ASIA PACIFIC (2014 AND 2024) 205
16.4.2 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 205
16.4.3 CHINA 210
16.4.3.1 AI-driven drug discovery reshapes pharmaceutical development strategies 210
16.4.4 JAPAN 215
16.4.4.1 Demographic pressures and innovation efficiency drive biosimulation adoption 215
16.4.5 INDIA 219
16.4.5.1 Cost-efficient innovation and clinical research expansion support growth 219
16.4.6 AUSTRALIA 223
16.4.6.1 Translational research ecosystem supports advanced development approaches 223
16.4.7 SOUTH KOREA 227
16.4.7.1 Government-led biotechnology ambitions accelerate digital drug development 227
16.4.8 REST OF ASIA PACIFIC 231
16.5 LATIN AMERICA 236
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 236
16.5.2 BRAZIL 240
16.5.2.1 Leading Regional Clinical Research Activity Drives Modeling Adoption 240
16.5.3 MEXICO 244
16.5.3.1 Nearshoring Trends Strengthen Pharmaceutical Development Capabilities 244
16.5.4 REST OF LATIN AMERICA 248
16.6 MIDDLE EAST & AFRICA 253
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 253
16.6.2 GCC COUNTRIES 257
16.6.2.1 National biotechnology strategies accelerate computational drug development 257
16.6.3 SAUDI ARABIA 262
16.6.3.1 Vision 2030 investments accelerate biotechnology and research capabilities 262
16.6.4 UAE 266
16.6.4.1 Innovation ecosystems and cross-border collaboration support growth 266
16.6.5 OTHER GCC COUNTRIES 270
16.6.6 SOUTH AFRICA 274
16.6.6.1 Growing clinical research activities and pharmaceutical innovation support biosimulation adoption 274
16.6.7 REST OF MIDDLE EAST & AFRICA 278
17 COMPETITIVE LANDSCAPE 283
17.1 OVERVIEW 283
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 283
17.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET 283
17.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 286
17.4 MARKET SHARE ANALYSIS, 2025 286
17.5 BRAND COMPARISON 289
17.6 VALUATION & FINANCIAL METRICS 290
17.6.1 FINANCIAL METRICS 290
17.6.2 COMPANY VALUATION 290
17.7 COMPANY EVALUATION MATRIX, KEY PLAYERS (2025) 291
17.7.1 STARS 291
17.7.2 EMERGING LEADERS 291
17.7.3 PERVASIVE PLAYERS 291
17.7.4 PARTICIPANTS 292
17.8 COMPANY FOOTPRINT: KEY PLAYERS, 2025 293
17.8.1 COMPANY FOOTPRINT 293
17.8.1.1 Region footprint 294
17.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 299
17.9.1 PROGRESSIVE COMPANIES 299
17.9.2 RESPONSIVE COMPANIES 299
17.9.3 DYNAMIC COMPANIES 299
17.9.4 STARTING BLOCKS 299
17.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 301
17.9.5.1 Detailed list of key startups/SMEs 301
17.9.5.2 Competitive benchmarking of startups/SMEs 302
17.10 COMPETITIVE SCENARIO 303
17.10.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 303
17.10.2 DEALS 304
17.10.3 OTHER DEVELOPMENTS 305
18 COMPANY PROFILES 306
18.1 KEY PLAYERS 306
18.1.1 CERTARA 306
18.1.1.1 Business overview 306
18.1.1.2 Products & services offered 308
18.1.1.3 Recent developments 310
18.1.1.3.1 Product launches & enhancements 310
18.1.1.3.2 Deals 313
18.1.1.3.3 Other developments 314
18.1.1.4 MnM view 314
18.1.1.4.1 Right to win 314
18.1.1.4.2 Strategic choices 314
18.1.1.4.3 Weaknesses & competitive threats 315
18.1.2 DASSAULT SYSTÈMES 316
18.1.2.1 Business overview 316
18.1.2.2 Products & services offered 318
18.1.2.3 Recent developments 319
18.1.2.3.1 Product launches & enhancements 319
18.1.2.3.2 Deals 321
18.1.2.3.3 Other developments 322
18.1.2.4 MnM view 322
18.1.2.4.1 Right to win 322
18.1.2.4.2 Strategic choices 322
18.1.2.4.3 Weaknesses & competitive threats 322
18.1.3 SCHRÖDINGER, INC. 323
18.1.3.1 Business overview 323
18.1.3.2 Products & services offered 325
18.1.3.3 Recent developments 326
18.1.3.3.1 Product launches & enhancements 326
18.1.3.3.2 Deals 327
18.1.3.3.3 Other developments 328
18.1.3.4 MnM view 328
18.1.3.4.1 Right to win 328
18.1.3.4.2 Strategic choices 328
18.1.3.4.3 Weaknesses & competitive threats 329
18.1.4 SIMULATIONS PLUS 330
18.1.4.1 Business overview 330
18.1.4.2 Products & services offered 332
18.1.4.3 Recent Developments 335
18.1.4.3.1 Product launches & enhancements 335
18.1.4.3.2 Deals 336
18.1.4.3.3 Other developments 338
18.1.4.4 MnM view 339
18.1.4.4.1 Right to win 339
18.1.4.4.2 Strategic choices 339
18.1.4.4.3 Weaknesses & competitive threats 339
18.1.5 GENEDATA AG (A DANAHER COMPANY) 340
18.1.5.1 Business overview 340
18.1.5.2 Products & services offered 342
18.1.5.3 Recent developments 342
18.1.5.3.1 Product launches & enhancements 342
18.1.5.3.2 Deals 343
18.1.5.4 MnM view 343
18.1.5.4.1 Right to win 343
18.1.5.4.2 Strategic choices 343
18.1.5.4.3 Weaknesses & competitive threats 343
18.1.6 ADVANCED CHEMISTRY DEVELOPMENT, INC. 344
18.1.6.1 Business overview 344
18.1.6.2 Products & Services Offered 345
18.1.6.3 Recent developments 345
18.1.6.3.1 Product launches & enhancements 345
18.1.6.3.2 Deals 346
18.1.7 CHEMICAL COMPUTING GROUP ULC 347
18.1.7.1 Business overview 347
18.1.7.2 Products & services offered 348
18.1.7.3 Recent developments 348
18.1.7.3.1 Product launches & enhancements 348
18.1.7.3.2 Other developments 349
18.1.8 PHYSIOMICS PLC 350
18.1.8.1 Business overview 350
18.1.8.2 Products & services offered 351
18.1.8.3 Recent developments 352
18.1.8.3.1 Product launches & enhancements 352
18.1.8.3.2 Other developments 353
18.1.9 INSILICO MEDICINE 354
18.1.9.1 Business overview 354
18.1.9.2 Products & services offered 355
18.1.9.3 Recent developments 356
18.1.9.3.1 Product launches & enhancements 356
18.1.9.3.2 Deals 357
18.1.10 ROSA & CO. LLC 358
18.1.10.1 Business overview 358
18.1.10.2 Products & services offered 358
18.1.10.3 Recent developments 359
18.1.10.3.1 Deals 359
18.1.11 AITIA 360
18.1.11.1 Business overview 360
18.1.11.2 Products & services offered 361
18.1.11.3 Recent developments 361
18.1.11.3.1 Deals 361
18.1.12 INSTEM PLC 362
18.1.12.1 Business overview 362
18.1.12.2 Products & services offered 362
18.1.12.3 Recent developments 363
18.1.12.3.1 Product enhancements 363
18.1.12.3.2 Deals 363
18.1.13 ALLUCENT 364
18.1.13.1 Business overview 364
18.1.13.2 Products & services offered 364
18.1.13.3 Recent developments 365
18.1.13.3.1 Deals 365
18.1.13.3.2 Other developments 365
18.1.14 OPENEYE, CADENCE MOLECULAR SCIENCES 366
18.1.14.1 Business overview 366
18.1.14.2 Products & services offered 367
18.1.14.3 Recent developments 368
18.1.14.3.1 Product enhancements 368
18.1.14.3.2 Deals 369
18.1.14.3.3 Expansions 369
18.1.15 THE MATHWORKS, INC. 370
18.1.15.1 Business overview 370
18.1.15.2 Products & services offered 371
18.1.15.3 Recent developments 371
18.1.15.3.1 Product enhancements 371
18.1.16 VERISIM LIFE 372
18.1.16.1 Business overview 372
18.1.16.2 Products & services offered 372
18.1.16.3 Recent developments 373
18.1.16.3.1 Product launches & enhancements 373
18.1.16.3.2 Deals 373
18.1.16.3.3 Other developments 374
18.1.17 NETABOLICS 375
18.1.17.1 Business overview 375
18.1.17.2 Products & services offered 375
18.1.18 CHARNWOOD DISCOVERY 376
18.1.18.1 Business overview 376
18.1.18.2 Products & services offered 377
18.1.18.3 Recent developments 377
18.1.18.3.1 Deals 377
18.1.19 CELLWORKS GROUP, INC. 378
18.1.19.1 Business overview 378
18.1.19.2 Products & services offered 379
18.1.19.3 Recent developments 379
18.1.19.3.1 Product launches & enhancements 379
18.1.19.3.2 Other developments 380
18.1.20 IN SILICO BIOSCIENCES 381
18.1.20.1 Business overview 381
18.1.20.2 Products & services offered 382
18.2 OTHER PLAYERS 383
18.2.1 NOVA 383
18.2.2 INSITRO 384
18.2.3 SCM – SOFTWARE CHEMISTRY & MATERIALS 385
18.2.4 BIOSYMETRICS, INC. 385
18.2.5 METRUM RESEARCH GROUP 386
19 RESEARCH METHODOLOGY 387
19.1 RESEARCH APPROACH 387
19.1.1 SECONDARY RESEARCH 388
19.1.1.1 Key data from secondary sources 389
19.1.2 PRIMARY RESEARCH 389
19.1.2.1 Primary sources 390
19.1.2.2 Key data from primary sources 391
19.1.2.3 Breakdown of primaries 391
19.1.2.4 Insights from primary experts 392
19.2 RESEARCH METHODOLOGY 392
19.3 MARKET SIZE ESTIMATION 394
19.4 MARKET BREAKDOWN DATA TRIANGULATION 399
19.5 MARKET SHARE ESTIMATION 400
19.6 STUDY ASSUMPTIONS 400
19.7 RESEARCH LIMITATIONS 401
19.7.1 METHODOLOGY-RELATED LIMITATIONS 401
19.8 RISK ASSESSMENT 401
20 APPENDIX 402
20.1 DISCUSSION GUIDE 402
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 408
20.3 CUSTOMIZATION OPTIONS 410
20.4 RELATED REPORTS 410
20.5 AUTHOR DETAILS 411

LIST OF TABLES

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 38
TABLE 2 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 61
TABLE 3 BIOSIMULATION MARKET: ROLE IN ECOSYSTEM 66
TABLE 4 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY OFFERING (2025) 67
TABLE 5 INDICATIVE PRICE FOR BIOSIMULATION MARKET, BY REGION (2025) 68
TABLE 6 CASE 1: MODEL-INFORMED DEVELOPMENT FOR SLEEPING SICKNESS TREATMENT 71
TABLE 7 CASE 2: PBPK MODELING TO SUPPORT WIDER DISSOLUTION SPECIFICATIONS WITHOUT ADDITIONAL CLINICAL TRIALS 72
TABLE 8 CASE 3: COMPUTATIONAL MODELING TO ADVANCE AN ONCOLOGY
DEVELOPMENT CANDIDATE 73
TABLE 9 US ADJUSTED RECIPROCAL TARIFF RATES 74
TABLE 10 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR
BIOSIMULATION MARKET 81
TABLE 11 BIOSIMULATION MARKET: KEY PATENTS 83
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 92
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 17 REGULATORY SCENARIO OF NORTH AMERICA 94
TABLE 18 REGULATORY SCENARIO OF EUROPE 94
TABLE 19 REGULATORY SCENARIO OF ASIA PACIFIC 95
TABLE 20 REGULATORY SCENARIO OF LATIN AMERICA 95
TABLE 21 REGULATORY SCENARIO OF MIDDLE EAST & AFRICA 96
TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
TOP THREE END USERS (%) 99
TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 100
TABLE 24 UNMET NEEDS IN BIOSIMULATION MARKET 102
TABLE 25 END-USER EXPECTATIONS IN BIOSIMULATION MARKET 103
TABLE 26 BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 105
TABLE 27 BIOSIMULATION MARKET FOR SOFTWARE, BY REGION,
2024–2031 (USD MILLION) 106
TABLE 28 BIOSIMULATION MARKET FOR SERVICES, BY TYPE, 2024–2031 (USD MILLION) 107
TABLE 29 BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2024–2031 (USD MILLION) 108
TABLE 30 BIOSIMULATION MARKET FOR CONSULTING & ADVISORY, BY REGION,
2024–2031 (USD MILLION) 109
TABLE 31 BIOSIMULATION MARKET FOR IMPLEMENTATION, TRAINING, AND SUPPORT,
BY REGION, 2024–2031 (USD MILLION) 110
TABLE 32 BIOSIMULATION MARKET FOR DATA ANALYSIS & INTERPRETATION,
BY REGION, 2024–2031 (USD MILLION) 111
TABLE 33 BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 113
TABLE 34 BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION,
2024–2031 (USD MILLION) 114
TABLE 35 BIOSIMULATION MARKET FOR PRECLINICAL DEVELOPMENT, BY REGION,
2024–2031 (USD MILLION) 115
TABLE 36 BIOSIMULATION MARKET FOR EARLY CLINICAL DEVELOPMENT, BY REGION,
2024–2031 (USD MILLION) 116
TABLE 37 BIOSIMULATION MARKET FOR LATE CLINICAL DEVELOPMENT, BY REGION,
2024–2031 (USD MILLION) 117
TABLE 38 BIOSIMULATION MARKET FOR REGULATORY, BY REGION,
2024–2031 (USD MILLION) 118
TABLE 39 BIOSIMULATION MARKET FOR COMMERCIAL & MARKET ACCESS, BY REGION, 2024–2031 (USD MILLION) 119
TABLE 40 BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 121
TABLE 41 BIOSIMULATION MARKET FOR ANTIBODY DESIGN, BY REGION,
2024–2031 (USD MILLION) 122
TABLE 42 BIOSIMULATION MARKET FOR PEPTIDE DISCOVERY, BY REGION,
2024–2031 (USD MILLION) 123
TABLE 43 BIOSIMULATION MARKET FOR ENZYME ENGINEERING, BY REGION,
2024–2031 (USD MILLION) 124
TABLE 44 BIOSIMULATION MARKET FOR BIFUNCTIONAL DEGRADERS, BY REGION,
2024–2031 (USD MILLION) 125
TABLE 45 BIOSIMULATION MARKET FOR TCR MODELING, BY REGION,
2024–2031 (USD MILLION) 126
TABLE 46 BIOSIMULATION MARKET FOR OTHER MODALITIES, BY REGION,
2024–2031 (USD MILLION) 127
TABLE 47 BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 129
TABLE 48 BIOSIMULATION MARKET FOR MOLECULAR DESIGN & OPTIMIZATION, BY REGION, 2024–2031 (USD MILLION) 130
TABLE 49 BIOSIMULATION MARKET FOR PK/PD MODELING, BY REGION,
2024–2031 (USD MILLION) 131
TABLE 50 BIOSIMULATION MARKET FOR PBPK MODELING, BY REGION,
2024–2031 (USD MILLION) 132
TABLE 51 BIOSIMULATION MARKET FOR QUANTITATIVE SYSTEMS PHARMACOLOGY,
BY REGION 2024–2031 (USD MILLION) 133
TABLE 52 BIOSIMULATION MARKET FOR ADME/TOXICITY PREDICTION, BY REGION,
2024–2031 (USD MILLION) 135
TABLE 53 BIOSIMULATION MARKET FOR CLINICAL TRIAL SIMULATION, BY REGION,
2024–2031 (USD MILLION) 136
TABLE 54 BIOSIMULATION MARKET FOR DISEASE MODELING, BY REGION,
2024–2031 (USD MILLION) 137
TABLE 55 BIOSIMULATION MARKET FOR OTHER APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 138
TABLE 56 BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 140
TABLE 57 BIOSIMULATION MARKET FOR ONCOLOGY, BY REGION,
2024–2031 (USD MILLION) 141
TABLE 58 BIOSIMULATION MARKET FOR CARDIOVASCULAR DISEASES, BY REGION,
2024–2031 (USD MILLION) 142
TABLE 59 BIOSIMULATION MARKET FOR NEUROLOGICAL DISORDERS, BY REGION,
2024–2031 (USD MILLION) 143
TABLE 60 BIOSIMULATION MARKET FOR INFECTIOUS DISEASES, BY REGION,
2024–2031 (USD MILLION) 144
TABLE 61 BIOSIMULATION MARKET FOR METABOLIC & ENDOCRINE DISORDERS,
BY REGION, 2024–2031 (USD MILLION) 145
TABLE 62 BIOSIMULATION MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,
2024–2031 (USD MILLION) 146
TABLE 63 BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 148
TABLE 64 BIOSIMULATION MARKET FOR ON-PREMISE MODELS, BY REGION,
2024–2031 (USD MILLION) 149
TABLE 65 BIOSIMULATION MARKET FOR CLOUD-BASED MODELS, BY REGION,
2024–2031 (USD MILLION) 150
TABLE 66 BIOSIMULATION MARKET FOR HYBRID MODELS, BY REGION,
2024–2031 (USD MILLION) 151
TABLE 67 BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 153
TABLE 68 BIOSIMULATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 154
TABLE 69 BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 155
TABLE 70 BIOSIMULATION MARKET FOR CONSULTING SERVICE COMPANIES, BY REGION, 2024–2031 (USD MILLION) 156
TABLE 71 REGULATORY BODIES MARKET FOR REGULATORY BODIES, BY REGION,
2024–2031 (USD MILLION) 157
TABLE 72 BIOSIMULATION MARKET FOR OTHER END USERS, BY REGION,
2024–2031 (USD MILLION) 158
TABLE 73 BIOSIMULATION MARKET, BY REGION, 2024–2031 (USD MILLION) 160
TABLE 74 NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 162
TABLE 75 NORTH AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 162
TABLE 76 NORTH AMERICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 162
TABLE 77 NORTH AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 163
TABLE 78 NORTH AMERICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 163
TABLE 79 NORTH AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 164
TABLE 80 NORTH AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 164
TABLE 81 NORTH AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 165
TABLE 82 NORTH AMERICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 165
TABLE 83 US: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 166
TABLE 84 US: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 166
TABLE 85 US: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 167
TABLE 86 US: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 167
TABLE 87 US: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 168
TABLE 88 US: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 168
TABLE 89 US: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 169
TABLE 90 US: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 169
TABLE 91 CANADA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 170
TABLE 92 CANADA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 171
TABLE 93 CANADA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 171
TABLE 94 CANADA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 172
TABLE 95 CANADA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 172
TABLE 96 CANADA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 173
TABLE 97 CANADA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 173
TABLE 98 CANADA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 174
TABLE 99 EUROPE: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 100 EUROPE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 176
TABLE 101 EUROPE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 176
TABLE 102 EUROPE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 177
TABLE 103 EUROPE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 177
TABLE 104 EUROPE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 178
TABLE 105 EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 178
TABLE 106 EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 179
TABLE 107 EUROPE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 179
TABLE 108 GERMANY: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 180
TABLE 109 GERMANY: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 180
TABLE 110 GERMANY: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 181
TABLE 111 GERMANY: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 181
TABLE 112 GERMANY: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 182
TABLE 113 GERMANY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 182
TABLE 114 GERMANY: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 183
TABLE 115 GERMANY: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 183
TABLE 116 FRANCE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 184
TABLE 117 FRANCE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 184
TABLE 118 FRANCE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 185
TABLE 119 FRANCE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 185
TABLE 120 FRANCE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 186
TABLE 121 FRANCE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 186
TABLE 122 FRANCE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 187
TABLE 123 FRANCE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 187
TABLE 124 UK: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 188
TABLE 125 UK: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 188
TABLE 126 UK: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 189
TABLE 127 UK: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 189
TABLE 128 UK: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 190
TABLE 129 UK: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 190
TABLE 130 UK: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 191
TABLE 131 UK: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 191
TABLE 132 ITALY: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 192
TABLE 133 ITALY: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 192
TABLE 134 ITALY: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 193
TABLE 135 ITALY: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 193
TABLE 136 ITALY: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 194
TABLE 137 ITALY: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 194
TABLE 138 ITALY: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 195
TABLE 139 ITALY: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 195
TABLE 140 SPAIN: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 196
TABLE 141 SPAIN: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 196
TABLE 142 SPAIN: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 197
TABLE 143 SPAIN: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 197
TABLE 144 SPAIN: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 198
TABLE 145 SPAIN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 198
TABLE 146 SPAIN: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 199
TABLE 147 SPAIN: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 199
TABLE 148 REST OF EUROPE: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 200
TABLE 149 REST OF EUROPE: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 201
TABLE 150 REST OF EUROPE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 201
TABLE 151 REST OF EUROPE: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 202
TABLE 152 REST OF EUROPE: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 202
TABLE 153 REST OF EUROPE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 203
TABLE 154 REST OF EUROPE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 203
TABLE 155 REST OF EUROPE: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 204
TABLE 156 ASIA PACIFIC: BIOSIMULATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 157 ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 207
TABLE 158 ASIA PACIFIC: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 207
TABLE 159 ASIA PACIFIC: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 208
TABLE 160 ASIA PACIFIC: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 208
TABLE 161 ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 209
TABLE 162 ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 209
TABLE 163 ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 210
TABLE 164 ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 210
TABLE 165 CHINA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 211
TABLE 166 CHINA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 212
TABLE 167 CHINA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 212
TABLE 168 CHINA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 213
TABLE 169 CHINA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 213
TABLE 170 CHINA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 214
TABLE 171 CHINA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 214
TABLE 172 CHINA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 215
TABLE 173 JAPAN: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 216
TABLE 174 JAPAN: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 216
TABLE 175 JAPAN: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 217
TABLE 176 JAPAN: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 217
TABLE 177 JAPAN: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 218
TABLE 178 JAPAN: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 218
TABLE 179 JAPAN: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 219
TABLE 180 JAPAN: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 219
TABLE 181 INDIA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 220
TABLE 182 INDIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 220
TABLE 183 INDIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 221
TABLE 184 INDIA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 221
TABLE 185 INDIA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 222
TABLE 186 INDIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 222
TABLE 187 INDIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 223
TABLE 188 INDIA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 223
TABLE 189 AUSTRALIA: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 224
TABLE 190 AUSTRALIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 224
TABLE 191 AUSTRALIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 225
TABLE 192 AUSTRALIA: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 225
TABLE 193 AUSTRALIA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 226
TABLE 194 AUSTRALIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 226
TABLE 195 AUSTRALIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 227
TABLE 196 AUSTRALIA: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 227
TABLE 197 SOUTH KOREA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 228
TABLE 198 SOUTH KOREA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 228
TABLE 199 SOUTH KOREA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 229
TABLE 200 SOUTH KOREA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 229
TABLE 201 SOUTH KOREA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 230
TABLE 202 SOUTH KOREA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 230
TABLE 203 SOUTH KOREA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 231
TABLE 204 SOUTH KOREA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 231
TABLE 205 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 232
TABLE 206 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 232
TABLE 207 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 233
TABLE 208 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 233
TABLE 209 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 234
TABLE 210 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 234
TABLE 211 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 235
TABLE 212 REST OF ASIA PACIFIC: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 235
TABLE 213 LATIN AMERICA: BIOSIMULATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 237
TABLE 214 LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 237
TABLE 215 LATIN AMERICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 237
TABLE 216 LATIN AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 238
TABLE 217 LATIN AMERICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 238
TABLE 218 LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 239
TABLE 219 LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 239
TABLE 220 LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 240
TABLE 221 LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 240
TABLE 222 BRAZIL: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 241
TABLE 223 BRAZIL: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 241
TABLE 224 BRAZIL: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 242
TABLE 225 BRAZIL: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 242
TABLE 226 BRAZIL: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 243
TABLE 227 BRAZIL: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 243
TABLE 228 BRAZIL: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 244
TABLE 229 BRAZIL: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 244
TABLE 230 MEXICO: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 245
TABLE 231 MEXICO: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 245
TABLE 232 MEXICO: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 246
TABLE 233 MEXICO: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 246
TABLE 234 MEXICO: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 247
TABLE 235 MEXICO: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 247
TABLE 236 MEXICO: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 248
TABLE 237 MEXICO: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 248
TABLE 238 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 249
TABLE 239 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 249
TABLE 240 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 250
TABLE 241 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 250
TABLE 242 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 251
TABLE 243 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 251
TABLE 244 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 252
TABLE 245 REST OF LATIN AMERICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 252
TABLE 246 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 254
TABLE 247 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 254
TABLE 248 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 254
TABLE 249 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 255
TABLE 250 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 255
TABLE 251 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 256
TABLE 252 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 256
TABLE 253 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 257
TABLE 254 MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 257
TABLE 255 GCC COUNTRIES: BIOSIMULATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 256 GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 258
TABLE 257 GCC COUNTRIES: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 259
TABLE 258 GCC COUNTRIES: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 259
TABLE 259 GCC COUNTRIES: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 260
TABLE 260 GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 260
TABLE 261 GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 261
TABLE 262 GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 261
TABLE 263 GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 262
TABLE 264 SAUDI ARABIA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 263
TABLE 265 SAUDI ARABIA: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 263
TABLE 266 SAUDI ARABIA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 264
TABLE 267 SAUDI ARABIA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 264
TABLE 268 SAUDI ARABIA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 265
TABLE 269 SAUDI ARABIA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 265
TABLE 270 SAUDI ARABIA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 266
TABLE 271 SAUDI ARABIA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 266
TABLE 272 UAE: BIOSIMULATION MARKET, BY OFFERING, 2024–2031 (USD MILLION) 267
TABLE 273 UAE: BIOSIMULATION MARKET, BY SERVICE, 2024–2031 (USD MILLION) 267
TABLE 274 UAE: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 268
TABLE 275 UAE: BIOSIMULATION MARKET, BY MODALITY, 2024–2031 (USD MILLION) 268
TABLE 276 UAE: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 269
TABLE 277 UAE: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 269
TABLE 278 UAE: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 270
TABLE 279 UAE: BIOSIMULATION MARKET, BY END USER, 2024–2031 (USD MILLION) 270
TABLE 280 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 271
TABLE 281 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 271
TABLE 282 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 272
TABLE 283 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 272
TABLE 284 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 273
TABLE 285 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 273
TABLE 286 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 274
TABLE 287 OTHER GCC COUNTRIES: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 274
TABLE 288 SOUTH AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 275
TABLE 289 SOUTH AFRICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 275
TABLE 290 SOUTH AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT,
2024–2031 (USD MILLION) 276
TABLE 291 SOUTH AFRICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 276
TABLE 292 SOUTH AFRICA: BIOSIMULATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 277
TABLE 293 SOUTH AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA,
2024–2031 (USD MILLION) 277
TABLE 294 SOUTH AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE,
2024–2031 (USD MILLION) 278
TABLE 295 SOUTH AFRICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 278
TABLE 296 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY OFFERING,
2024–2031 (USD MILLION) 279
TABLE 297 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY SERVICE,
2024–2031 (USD MILLION) 279
TABLE 298 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY PHASE OF DEVELOPMENT, 2024–2031 (USD MILLION) 280
TABLE 299 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY MODALITY,
2024–2031 (USD MILLION) 280
TABLE 300 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 281
TABLE 301 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY THERAPEUTIC AREA, 2024–2031 (USD MILLION) 281
TABLE 302 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY DEPLOYMENT MODE, 2024–2031 (USD MILLION) 282
TABLE 303 REST OF MIDDLE EAST & AFRICA: BIOSIMULATION MARKET, BY END USER,
2024–2031 (USD MILLION) 282
TABLE 304 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOSIMULATION MARKET, JANUARY 2023– JUNE 2026 283
TABLE 305 BIOSIMULATION MARKET: DEGREE OF COMPETITION 287
TABLE 306 BIOSIMULATION MARKET: REGION FOOTPRINT (20 COMPANIES) 294
TABLE 307 BIOSIMULATION MARKET: OFFERING FOOTPRINT (20 COMPANIES) 295
TABLE 308 BIOSIMULATION MARKET: PHASE OF DEVELOPMENT FOOTPRINT (20 COMPANIES) 296
TABLE 309 BIOSIMULATION MARKET: MODALITY FOOTPRINT (20 COMPANIES) 297
TABLE 310 BIOSIMULATION MARKET: END USER FOOTPRINT (20 COMPANIES) 298
TABLE 311 BIOSIMULATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 301
TABLE 312 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY REGION 302
TABLE 313 BIOSIMULATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS, BY COMPONENT 302
TABLE 314 BIOSIMULATION MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2023–JUNE 2026 303
TABLE 315 BIOSIMULATION MARKET: DEALS, JANUARY 2023–JUNE 2026 304
TABLE 316 BIOSIMULATION MARKET: OTHER DEVELOPMENTS, JANUARY 2023–JUNE 2026 305
TABLE 317 CERTARA: COMPANY OVERVIEW 306
TABLE 318 CERTARA: PRODUCTS & SERVICES OFFERED 308
TABLE 319 CERTARA: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 310
TABLE 320 CERTARA: DEALS, JANUARY 2023−JUNE 2026 313
TABLE 321 CERTARA: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 314
TABLE 322 DASSAULT SYSTÈMES: COMPANY OVERVIEW 316
TABLE 323 DASSAULT SYSTÈMES: PRODUCTS & SERVICES OFFERED 318
TABLE 324 DASSAULT SYSTÈMES: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023− JUNE 2026 319
TABLE 325 DASSAULT SYSTÈMES: DEALS, JANUARY 2023− JUNE 2026 321
TABLE 326 DASSAULT SYSTÈMES: OTHER DEVELOPMENTS, JANUARY 2023− JUNE 2026 322
TABLE 327 SCHRÖDINGER, INC.: COMPANY OVERVIEW 323
TABLE 328 SCHRÖDINGER, INC.: PRODUCTS & SERVICES OFFERED 325
TABLE 329 SCHRÖDINGER, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023− JUNE 2026 326
TABLE 330 SCHRÖDINGER, INC.: DEALS, JANUARY 2023−JUNE 2026 327
TABLE 331 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS, JANUARY 2023− JUNE 2026 328
TABLE 332 SIMULATIONS PLUS: COMPANY OVERVIEW 330
TABLE 333 SIMULATIONS PLUS: PRODUCTS & SERVICES OFFERED 332
TABLE 334 SIMULATIONS PLUS: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JUNE 2026 335
TABLE 335 SIMULATIONS PLUS: DEALS, JANUARY 2023−JUNE 2026 336
TABLE 336 SIMULATIONS PLUS: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 338
TABLE 337 GENEDATA AG (A DANAHER COMPANY): COMPANY OVERVIEW 340
TABLE 338 GENEDATA AG (A DANAHER COMPANY): PRODUCTS & SERVICES OFFERED 342
TABLE 339 GENEDATA AG (A DANAHER COMPANY): PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 342
TABLE 340 GENEDATA AG (A DANAHER COMPANY): DEALS, JANUARY 2023−JUNE 2026 343
TABLE 341 ADVANCED CHEMISTRY DEVELOPMENT, INC.: COMPANY OVERVIEW 344
TABLE 342 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCTS & SERVICES OFFERED 345
TABLE 343 ADVANCED CHEMISTRY DEVELOPMENT, INC.: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 345
TABLE 344 ADVANCED CHEMISTRY DEVELOPMENT, INC.: DEALS, JANUARY 2023−JUNE 2026 346
TABLE 345 CHEMICAL COMPUTING GROUP ULC: COMPANY OVERVIEW 347
TABLE 346 CHEMICAL COMPUTING GROUP ULC: PRODUCTS & SERVICES OFFERED 348
TABLE 347 CHEMICAL COMPUTING GROUP ULC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2023−JUNE 2026 348
TABLE 348 CHEMICAL COMPUTING GROUP ULC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 349
TABLE 349 PHYSIOMICS PLC: COMPANY OVERVIEW 350
TABLE 350 PHYSIOMICS PLC: PRODUCTS & SERVICES OFFERED 351
TABLE 351 PHYSIOMICS PLC: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021−JANUARY 2025 352
TABLE 352 PHYSIOMICS PLC: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 353
TABLE 353 INSILICO MEDICINE: COMPANY OVERVIEW 354
TABLE 354 INSILICO MEDICINE: PRODUCTS & SERVICES OFFERED 355
TABLE 355 INSILICO MEDICINE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JUNE 2026 356
TABLE 356 INSILICO MEDICINE: DEALS, JANUARY 2023−JUNE 2026 357
TABLE 357 ROSA & CO. LLC: COMPANY OVERVIEW 358
TABLE 358 ROSA & CO. LLC: PRODUCTS & SERVICES OFFERED 358
TABLE 359 ROSA & CO. LLC: DEALS, JANUARY 2023−JUNE 2026 359
TABLE 360 AITIA: COMPANY OVERVIEW 360
TABLE 361 AITIA: PRODUCTS & SERVICES OFFERED 361
TABLE 362 AITIA: DEALS, JANUARY 2023−JUNE 2026 361
TABLE 363 INSTEM PLC: COMPANY OVERVIEW 362
TABLE 364 INSTEM PLC: PRODUCTS & SERVICES OFFERED 362
TABLE 365 INSTEM PLC: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 363
TABLE 366 INSTEM PLC: DEALS, JANUARY 2023−JUNE 2026 363
TABLE 367 ALLUCENT: COMPANY OVERVIEW 364
TABLE 368 ALLUCENT: PRODUCTS & SERVICES OFFERED 364
TABLE 369 ALLUCENT: DEALS, JANUARY 2023−JUNE 2026 365
TABLE 370 ALLUCENT: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 365
TABLE 371 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY OVERVIEW 366
TABLE 372 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCTS & SERVICES OFFERED 367
TABLE 373 OPENEYE, CADENCE MOLECULAR SCIENCES: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 368
TABLE 374 OPENEYE, CADENCE MOLECULAR SCIENCES: DEALS, JANUARY 2023−JUNE 2026 369
TABLE 375 OPENEYE, CADENCE MOLECULAR SCIENCES: EXPANSIONS,
JANUARY 2023−JUNE 2026 369
TABLE 376 THE MATHWORKS, INC.: COMPANY OVERVIEW 370
TABLE 377 THE MATHWORKS, INC.: PRODUCTS & SERVICES OFFERED 371
TABLE 378 THE MATHWORKS, INC.: PRODUCT ENHANCEMENTS, JANUARY 2023−JUNE 2026 371
TABLE 379 VERISIM LIFE: COMPANY OVERVIEW 372
TABLE 380 VERISIM LIFE: PRODUCTS & SERVICES OFFERED 372
TABLE 381 VERISIM LIFE: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JUNE 2026 373
TABLE 382 VERISIM LIFE: DEALS, JANUARY 2023−JUNE 2026 373
TABLE 383 VERISIM LIFE: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 374
TABLE 384 NETABOLICS: COMPANY OVERVIEW 375
TABLE 385 NETABOLICS: PRODUCTS & SERVICES OFFERED 375
TABLE 386 CHARNWOOD DISCOVERY: COMPANY OVERVIEW 376
TABLE 387 CHARNWOOD DISCOVERY: PRODUCTS & SERVICES OFFERED 377
TABLE 388 CHARNWOOD DISCOVERY: DEALS, JANUARY 2023−JUNE 2026 377
TABLE 389 CELLWORKS GROUP, INC.: COMPANY OVERVIEW 378
TABLE 390 CELLWORKS GROUP, INC.: PRODUCTS & SERVICES OFFERED 379
TABLE 391 CELLWORKS GROUP, INC.: PRODUCT LAUNCHES & ENHANCEMENTS,
JANUARY 2023−JUNE 2026 379
TABLE 392 CELLWORKS GROUP, INC.: OTHER DEVELOPMENTS, JANUARY 2023−JUNE 2026 380
TABLE 393 IN SILICO BIOSCIENCES: COMPANY OVERVIEW 381
TABLE 394 IN SILICO BIOSCIENCES: PRODUCTS & SERVICES OFFERED 382
TABLE 395 RISK ASSESSMENT: BIOSIMULATION MARKET 401

LIST OF FIGURES

FIGURE 1 BIOSIMULATION MARKET SEGMENTATION 35
FIGURE 2 MARKET SCENARIO 42
FIGURE 3 GLOBAL BIOSIMULATION MARKET, 2024–2031 42
FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN
BIOSIMULATION MARKET, 2023–2026 43
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF BIOSIMULATION MARKET 44
FIGURE 6 HIGH-GROWTH SEGMENTS IN BIOSIMULATION MARKET, 2026–2031 45
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN BIOSIMULATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 46
FIGURE 8 INCREASING R&D INVESTMENTS IN PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO DRIVE GROWTH IN BIOSIMULATION MARKET 48
FIGURE 9 SOFTWARE IN NORTH AMERICA ACCOUNTED FOR LARGEST
MARKET SHARE IN 2025 49
FIGURE 10 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
FIGURE 11 BIOSIMULATION MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 52
FIGURE 12 BIOSIMULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 60
FIGURE 13 BIOSIMULATION MARKET: VALUE CHAIN ANALYSIS 64
FIGURE 14 BIOSIMULATION MARKET: ECOSYSTEM ANALYSIS 66
FIGURE 15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 70
FIGURE 17 PATENT PUBLICATION TRENDS IN BIOSIMULATION MARKET, 2015–2026 81
FIGURE 18 JURISDICTION AND TOP APPLICANT ANALYSIS FOR BIOSIMULATION MARKET 81
FIGURE 19 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR BIOSIMULATION MARKET (JANUARY 2015 TO JUNE 2026) 82
FIGURE 20 MARKET POTENTIAL OF AI/GEN AI ON BIOSIMULATION ACROSS INDUSTRIES 85
FIGURE 21 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 87
FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 99
FIGURE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS 100
FIGURE 24 NORTH AMERICA: BIOSIMULATION MARKET SNAPSHOT 161
FIGURE 25 ASIA PACIFIC: BIOSIMULATION MARKET SNAPSHOT 206
FIGURE 26 BIOSIMULATION MARKET: REVENUE ANALYSIS OF KEY PLAYERS 286
FIGURE 27 BIOSIMULATION MARKET SHARE ANALYSIS OF KEY PLAYERS (2025) 287
FIGURE 28 BIOSIMULATION MARKET: BRAND COMPARATIVE ANALYSIS 289
FIGURE 29 EV/EBITDA OF KEY VENDORS 290
FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 290
FIGURE 31 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX, KEY PLAYERS (2025) 292
FIGURE 32 BIOSIMULATION MARKET: COMPANY FOOTPRINT 293
FIGURE 33 BIOSIMULATION MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2025 300
FIGURE 34 CERTARA: COMPANY SNAPSHOT (2025) 307
FIGURE 35 DASSAULT SYSTÈMES: COMPANY SNAPSHOT (2025) 317
FIGURE 36 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2025) 324
FIGURE 37 SIMULATIONS PLUS: COMPANY SNAPSHOT (2025) 331
FIGURE 38 GENEDATA AG (A DANAHER COMPANY): COMPANY SNAPSHOT (2025) 341
FIGURE 39 PHYSIOMICS PLC: COMPANY SNAPSHOT (2025) 351
FIGURE 40 INSILICO MEDICINE: COMPANY SNAPSHOT (2025) 355
FIGURE 41 OPENEYE, CADENCE MOLECULAR SCIENCES: COMPANY SNAPSHOT (2025) 367
FIGURE 42 RESEARCH DESIGN 387
FIGURE 43 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 391
FIGURE 44 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 393
FIGURE 45 BOTTOM-UP APPROACH 394
FIGURE 46 TOP-DOWN APPROACH 395
FIGURE 47 CAGR PROJECTIONS FROM ANALYSIS OF DROC IN BIOSIMULATION MARKET 396
FIGURE 48 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 396
FIGURE 49 DATA TRIANGULATION METHODOLOGY 399

---

---